Redeye thinks that Lagercrantz yet again showed resiliency with strong margins and cash flow despite...
Suominen's Q4 comparable EBITDA remained virtually intact q/q, but fell short of Vara Research conse...
Board recommends shareholders to reject bid Q4 better than it looked at first glance 13x '24e EV/EBI...
Underlying earnings better than expected 4.2% organic sales growth in Q4 Near-term uncertainty persi...
Q4 NOI -2% vs ABGSCe Earnings capacity IFPM -3% vs ABGSC 2024e Higher DPS and reiterate acquisition ...
EBITA SEK 177m (-11% vs. ABGSCe, -9% vs. cons) We expect cons.
Q4e: 8% org. top line growth on tough comps Earnings growth remains very strong, adj.
Q4 EBITDA of 21.5m vs ABGSCe 20.1m Initiates strategic review of portfolio Downwards revision to con...
Suominen’s result were largely in line with Q3 and fell short of Vara Research consensus expectation...
More baseline falls vs. expected implies higher likelihood of effect New guidance: completion of stu...
EBIT +5% vs. ABGSCe, 21% org. growth, 39% margins (ABGSCe 36%) Slightly slower ramp-up vs.
Board recommends shareholders to REJECT Kingspan bid Increases the chance of a raised bid, in our vi...
Redeye comments on GiG ahead of its Q4-results (due 14 February) where we expect the company to deli...
Redeye comments on Scandion Oncology presenting more details on CORIST part 3 results at its recent ...
Q4: Clean EBIT of SEK -100m Pulp prices up and demand better Fair value range: SEK 9-16/sh Q4: Figu...
Q4e revenue ~NOK 306m Sainsbury's contract a positive development, but more orders needed Estimates ...
Analyst Group has entered into an agreement with Pharma Equity Group on commissioned research, inclu...
Redeye shares its preview of BONESUPPORT’s Q4 2023e results, due February 15.
Equity analyst interviews Elanders' CEO Magnus Nilsson and CFO Andreas Wikner after their Q4.
Inför rapporten för det fjärde kvartalet förväntar sig Analysguiden tillväxt inom samtliga marknader...
.jpg)
